Aspirin use in patients with DM reduces the composite endpoint of CV death, non-fatal MI and stroke compared with a placebo. However, routine use of aspirin for primary prevention among diabetic patients cannot be advised due to the increased risk of major bleeding. These findings suggest careful risk assessment of individual patients.
Keyphrases
- cardiovascular events
- coronary artery disease
- low dose
- cardiovascular disease
- risk assessment
- end stage renal disease
- atrial fibrillation
- newly diagnosed
- ejection fraction
- antiplatelet therapy
- chronic kidney disease
- systematic review
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- heavy metals
- clinical trial
- adipose tissue
- clinical practice
- skeletal muscle
- climate change
- patient reported